Cargando…
Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma
BACKGROUND: Skin cutaneous melanoma (SKCM) is an extremely malignant tumor and accounts for the majority of skin cancer deaths. Aspartate beta-hydroxylase domain containing 1 (ASPHD1) may participate in cancer progression through controlling α-ketoglutarate-dependent dioxygenases. However, its role...
Autores principales: | Sun, Shiquan, Deng, Min, Wen, Juan, Chen, Xiaoyuan, Xu, Jiaqi, Liu, Yu, Wan, Huanhuan, Wang, Jin, Yan, Leping, He, Yong, Xu, Yunsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063950/ https://www.ncbi.nlm.nih.gov/pubmed/37004045 http://dx.doi.org/10.1186/s12885-023-10625-8 |
Ejemplares similares
-
Machine learning-derived identification of tumor-infiltrating immune cell-related signature for improving prognosis and immunotherapy responses in patients with skin cutaneous melanoma
por: Leng, Shaolong, et al.
Publicado: (2023) -
Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma
por: Long, Shengyong, et al.
Publicado: (2023) -
Diverse molecular functions of aspartate β-hydroxylase in cancer
por: Zheng, Wenqian, et al.
Publicado: (2020) -
Aspartate β-hydroxylase as a target for cancer therapy
por: Kanwal, Madiha, et al.
Publicado: (2020) -
The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM)
por: Wu, Shaobo, et al.
Publicado: (2021)